Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05931471
Other study ID # FL119
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 19, 2023
Est. completion date June 30, 2024

Study information

Verified date May 2024
Source USDA, Western Human Nutrition Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research is to assess mucosal immune function responses in the gastrointestinal (GI) tract to twice-daily yogurt consumption. Previous research has shown that dairy yogurt intake can benefit gastrointestinal health. The current study will determine whether a dietary intervention with dairy yogurt will improve mucosal immunity and the gut microbiome.


Description:

The gastrointestinal (GI) tract has the difficult task of absorbing nutrients while excluding microorganisms and non-nutritive foreign agents. The GI tract is protected by components of GI mucosal immunity, such as the mucin layer, anti-microbial peptides, secretory IgA (sIgA), and more, which collectively maintain gut homeostasis. When mucosal immunity fails, the result can be gastrointestinal infection, allergic inflammation, or inflammatory bowel disease. Mechanistic knowledge from in vitro studies suggests that sIgA increases in response to lactic acid bacteria and mucin-2 expression increases in response to milk peptides in yogurt. Yogurt consumption may also reduce constipation and increase the production of short-chain fatty acids (SCFAs). SCFAs promote the health of intestinal cells by acting as an energy source, influencing gene expression, and exerting anti-inflammatory effects. When SCFAs increase, fecal pH decreases. This research will expand the limited existing literature on how GI mucosal immunity changes in response to yogurt consumption, the time frame over which effects occur and how long the effects persist after yogurt is discontinued. Participants will undergo a two-week baseline period without yogurt intake, followed by a three-week intervention of two daily 6-oz servings of dairy yogurt, and a follow-up period with no yogurt consumption. Stool samples will be collected at the end of the 2-week baseline period, after 1, 2, and 3 weeks of intervention, and at the end of the 2 weeks post-intervention period for measurement of fecal sIgA, fecal mucin-2 mRNA, fecal pH, and fecal SCFAs, and analysis of the fecal microbiome. 24-hour dietary recalls will be collected with the Automated Self-Administered Dietary Assessment Tool (ASA24) during the baseline and intervention phases of the trial. Specific knowledge will be produced regarding the effect of regular yogurt consumption on sIgA levels, mucin-2 gene expression and fecal pH in older adults (age 50 - 75 years). The study will also produce knowledge on the intervention length needed for maximal response in these outcome measures and how long these responses persist when the yogurt intervention is discontinued. The outcomes of this study will 1) provide preliminary data to inform design of future, larger studies on how dairy yogurt or similar cultured products influence GI mucosal immune function, and 2) contribute to growing knowledge on the potential health benefits of consuming fermented, particularly yogurt.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 32
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria: - Age 50 - 75 years - BMI 18.5 - 39.9 kg/m2 Exclusion Criteria: - BMI less than 18.5 or greater than 39.9 - Consumption of fermented foods or probiotics in the past two weeks - Unwillingness to abstain from non-study fermented foods and probiotics during the trial - Allergy to cow milk - Lactose intolerance - Any dietary restriction limiting or prohibiting consumption of lightly sweetened, vanilla flavored, whole milk yogurt - Uncomfortable with or unwilling to complete stool sample collections - Current participation in another research study - If female, - Currently pregnant or lactating - Have had menstrual bleeding in the past 12 months - Having fewer than 3 bowel movements per week - Unmanaged hypertension, defined as blood pressure greater than or equal to 140/90 mmHg - Current diagnosis of: - Disease that affects the immune system, including HIV/AIDS - Cancer - Diabetes - Asthma with daily medication - Primary immune deficiency - Auto-immune disease - Chronic gastrointestinal disorder (e.g. Crohn's disease, irritable bowel syndrome, colitis, gastric ulcer) - Current use for 2 weeks or longer of: - Any drug that affects the immune system, such as immunosuppressants, immune modifying drugs, or corticosteroids (e.g. cortisone, prednisone, methylprednisolone) - Biologics (e.g. Lantus, Remicade, Rituxan, Humira, Herceptin, Avastin, Lucentis, Enbrel) - Use of sulfonamides or antibiotics in the past 3 months - Use of laxatives in the past 2 weeks - Currently undergoing cancer treatment with radiation or drugs - History of gastrointestinal surgery that would impact study outcomes, such as gastric bypass, intestinal resection, surgeries of the liver or pancreas, or removal of part or all of any organ of the GI tract - Having within the past 2 weeks: - Diarrheal illness, defined as passing 3 or more abnormally loose or watery stools in a 24-hour period - Persistent vomiting - Fever - Having within the past 3 months: - Surgery - Hospitalization - Having within the past 1 month: - Colonoscopy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Yogurt Intervention
Participants will be provided with a commercial yogurt that contains only cultured dairy, traditional live active cultures (Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, and possibly other non-brand-specific strains), sugar, and, optionally, vanilla flavor. The yogurt will contain no starches or pectin, gums, fiber or other added ingredients. Participants will be asked to consume two 6-ounce portions of yogurt each day, and to log their consumption in a provided booklet. They will be advised to incorporate the yogurt into their diet however they choose (as part of meals or as snacks), to avoid other fermented foods, and to otherwise maintain their habitual diet.

Locations

Country Name City State
United States USDA Western Human Nutrition Research Center Davis California

Sponsors (1)

Lead Sponsor Collaborator
USDA, Western Human Nutrition Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in fecal secretory immunoglobulin A Fecal secretory immunoglobulin A (sIgA) will be extracted then measured in duplicate by enzyme-linked immunosorbent assay (ELISA) At end of 2-week baseline period; at 1, 2 and 3 weeks of intervention; and at end of 2-week follow-up period
Secondary Changes in fecal mucin-2 mRNA expression Pre-amplification and quantitative reverse transcription polymerase chair reaction (RT-qPCR) for mucin 2 (MUC2) and GAPDH will be conducted using validated TaqMan assays, and fold MUC2 gene expression of samples will be calculated relative to a commercial total human colon RNA standard using GAPDH as the housekeeping gene. At end of 2-week baseline period; at 1, 2 and 3 weeks of intervention; and at end of 2-week follow-up period
Secondary Changes in fecal pH Fecal pH will be measured with a glass electrode pH meter. At end of 2-week baseline period; at 1, 2 and 3 weeks of intervention; and at end of 2-week follow-up period
Secondary Changes in fecal short-chain fatty acids The most abundant fecal SCFAs, such as acetate, propionate, butyrate, will be analyzed via gas chromatography-mass spectrometry. At end of 2-week baseline period; at 1, 2 and 3 weeks of intervention; and at end of 2-week follow-up period
Secondary Fecal microbiome Gut microbiota composition will be assessed with PCR amplification and 16S sequencing At end of 2-week baseline period; at 1, 2 and 3 weeks of intervention; and at end of 2-week follow-up period
See also
  Status Clinical Trial Phase
Recruiting NCT05793112 - INF108F in Infants With Food Protein Induced Proctocolitis Phase 4
Active, not recruiting NCT04327141 - Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women N/A
Recruiting NCT04117321 - Mother-infant Microbiota Transmission and Its Link to the Health of the Baby
Recruiting NCT05655910 - Enhanced Nutritional Optimization in LVAD Trial N/A
Recruiting NCT03325855 - Fecal Microbiota Transplant National Registry
Recruiting NCT03797417 - Gut Microbiome and Metabolic Pathways Changes in Vitiligo
Withdrawn NCT06006416 - Effect of Fenugreek Fibre on Gut Microbiome Phase 3
Recruiting NCT06206486 - The Gut Microbiome and Serum Metabolites as a Biological Mechanism Underlying Pain in Kidney Transplantation
Completed NCT02655250 - Neonatal Microbiome Validity Study
Recruiting NCT05670288 - Impact of Gut Microbiome on Metabolic and Bowel Function During the First Year After Spinal Cord Injury
Not yet recruiting NCT03975764 - Fecal Microbiota in Preterm Birth
Completed NCT03219931 - NEOBIFI: Clinical Trial for the Prevention and/or Reduction of the Incidence of Colics in Infants Phase 4
Recruiting NCT04447365 - The Correlation Between Gut Microbiome-host Interaction and Ventricular Arrhythmias.
Recruiting NCT04466072 - Gut Microbiome and Ventricular Arrhythmias
Not yet recruiting NCT06130137 - Gut Microbiome in People Living With HIV and HBV
Recruiting NCT06260579 - Home-based Exercise and Physical Activity Intervention After Kidney Transplantation: Impact of Exercise Intensity N/A
Completed NCT04511052 - Probiotics for Enhanced Tissue Carotenoid Status in Premenopausal Women Phase 1/Phase 2
Active, not recruiting NCT06424691 - Infant Restore: Efficacy of Microbiome Analysis and Education N/A
Recruiting NCT06404749 - Fungal Fiber for Gut Health N/A
Not yet recruiting NCT06433310 - Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study Early Phase 1